Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBP NASDAQ:HROW NASDAQ:RZLT NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$30.27+12.2%$27.10$16.10▼$32.14$1.26B1.51359,186 shs1.31 million shsHROWHarrow$35.21-0.5%$36.03$25.68▼$54.85$1.32B0.341.02 million shs954,214 shsRZLTRezolute$3.30+0.9%$3.21$1.07▼$11.46$314.88M0.661.12 million shs1.50 million shsWVEWAVE Life Sciences$6.58+1.7%$7.45$5.02▼$21.73$1.24B-1.324.05 million shs3.55 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma+12.24%+13.24%+0.73%+31.78%+51.05%HROWHarrow-0.51%+6.70%-12.50%-35.01%+35.84%RZLTRezolute+0.92%+1.54%+5.77%+2.80%-16.46%WVEWAVE Life Sciences+1.70%+3.13%-6.67%-52.76%+8.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$30.27+12.2%$27.10$16.10▼$32.14$1.26B1.51359,186 shs1.31 million shsHROWHarrow$35.21-0.5%$36.03$25.68▼$54.85$1.32B0.341.02 million shs954,214 shsRZLTRezolute$3.30+0.9%$3.21$1.07▼$11.46$314.88M0.661.12 million shs1.50 million shsWVEWAVE Life Sciences$6.58+1.7%$7.45$5.02▼$21.73$1.24B-1.324.05 million shs3.55 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma+12.24%+13.24%+0.73%+31.78%+51.05%HROWHarrow-0.51%+6.70%-12.50%-35.01%+35.84%RZLTRezolute+0.92%+1.54%+5.77%+2.80%-16.46%WVEWAVE Life Sciences+1.70%+3.13%-6.67%-52.76%+8.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 2.82Moderate Buy$43.3843.29% UpsideHROWHarrow 2.64Moderate Buy$69.4397.18% UpsideRZLTRezolute 2.45Hold$8.75165.15% UpsideWVEWAVE Life Sciences 2.87Moderate Buy$27.25314.13% UpsideCurrent Analyst Ratings BreakdownLatest RZLT, AVBP, HROW, and WVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026AVBPArriVent BioPharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$43.00 ➝ $45.005/22/2026AVBPArriVent BioPharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/20/2026WVEWAVE Life Sciences Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$13.00 ➝ $14.005/19/2026WVEWAVE Life Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $13.005/14/2026RZLTRezolute Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.00 ➝ $10.005/13/2026HROWHarrow Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$91.00 ➝ $88.005/13/2026AVBPArriVent BioPharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$45.00 ➝ $43.005/12/2026HROWHarrow BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.005/4/2026WVEWAVE Life Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $24.005/4/2026AVBPArriVent BioPharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/30/2026WVEWAVE Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $43.00(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A$6.96 per shareN/AHROWHarrow$268.68M4.88$0.86 per share40.95$0.76 per share46.33RZLTRezoluteN/AN/AN/AN/A$1.21 per shareN/AWVEWAVE Life Sciences$71.80M17.63N/AN/A$2.66 per share2.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$166.31M-$3.47N/AN/AN/AN/A-48.98%-45.44%8/10/2026 (Estimated)HROWHarrow-$5.14M-$0.41N/A16.30N/A-5.57%19.59%2.26%8/10/2026 (Estimated)RZLTRezolute-$74.41M-$0.82N/AN/AN/AN/A-58.82%-54.48%N/AWVEWAVE Life Sciences-$204.38M-$1.06N/AN/AN/A-255.70%-56.76%-42.80%7/30/2026 (Estimated)Latest RZLT, AVBP, HROW, and WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q3 2026RZLTRezolute-$0.1686-$0.16+$0.0086-$0.16N/AN/A5/11/2026Q1 2026AVBPArriVent BioPharma-$0.88-$0.96-$0.08-$0.96N/AN/A5/11/2026Q1 2026HROWHarrow-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 million4/29/2026Q1 2026WVEWAVE Life Sciences-$0.34-$0.13+$0.21-$0.13$8.45 million$38.25 million3/5/2026Q4 2025AVBPArriVent BioPharma-$0.87-$0.78+$0.09-$0.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A13.9513.95HROWHarrow10.302.482.30RZLTRezoluteN/A15.8415.84WVEWAVE Life SciencesN/A11.2611.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%HROWHarrow72.76%RZLTRezolute82.97%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharma8.58%HROWHarrow12.80%RZLTRezolute14.78%WVEWAVE Life Sciences24.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4046.58 million42.58 millionN/AHROWHarrow18037.28 million32.50 millionOptionableRZLTRezolute4096.29 million82.06 millionOptionableWVEWAVE Life Sciences240192.40 million145.65 millionOptionableRZLT, AVBP, HROW, and WVE HeadlinesRecent News About These CompaniesAnalysts Are Bullish on Top Healthcare Stocks: Wave Life Sciences (WVE), Boston Scientific (BSX)May 29 at 10:43 PM | theglobeandmail.comWave Life Sciences Ltd. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their LossesMay 27 at 8:41 AM | globenewswire.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Rating of "Moderate Buy" from BrokeragesMay 27 at 2:16 AM | americanbankingnews.comShould WVE-006’s RNA-Editing AAT Data Shift the Risk-Reward Calculus for Wave Life Sciences (WVE) Investors?May 25, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), Gossamer Bio (GOSS) and Cullinan Management (CGEM)May 21, 2026 | theglobeandmail.comWhat is HC Wainwright's Forecast for WVE FY2028 Earnings?May 21, 2026 | marketbeat.comWave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD DataMay 20, 2026 | seekingalpha.comWVE stock edges up after positive early data for rare disease drugMay 20, 2026 | msn.comBeam one-ups Wave as both show promise of genetic editing for AATDMay 20, 2026 | biospace.comBFinancial Comparison: Tarsus Pharmaceuticals (NASDAQ:TARS) versus WAVE Life Sciences (NASDAQ:WVE)May 20, 2026 | americanbankingnews.comWave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1May 19, 2026 | prnewswire.comWave Life Sciences Ltd. (WVE) Shareholder/Analyst Call TranscriptMay 19, 2026 | seekingalpha.comWave Life Sciences Ltd. (WVE) Shareholder/Analyst Call - SlideshowMay 18, 2026 | seekingalpha.comWave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly DosingMay 18, 2026 | globenewswire.comWave Life Sciences (WVE) price target decreased by 15.26% to 23.97May 15, 2026 | msn.comWave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare ConferenceMay 13, 2026 | globenewswire.comGrowth Investors: Industry Analysts Just Upgraded Their Wave Life Sciences Ltd. (NASDAQ:WVE) Revenue Forecasts By 91%May 8, 2026 | finance.yahoo.comWave Life Sciences: Good Platform, Mixed Clinical Trial Data, HoldMay 7, 2026 | seekingalpha.comHC Wainwright Expects Higher Earnings for WAVE Life SciencesMay 4, 2026 | marketbeat.comCanaccord Genuity Reaffirms Their Buy Rating on Wave Life Sciences (WVE)May 3, 2026 | theglobeandmail.comA Look At Wave Life Sciences (WVE) Valuation After Sharp Year To Date Share Price DeclineMay 3, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRZLT, AVBP, HROW, and WVE Company DescriptionsArriVent BioPharma NASDAQ:AVBP$30.27 +3.30 (+12.24%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$29.11 -1.16 (-3.83%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Harrow NASDAQ:HROW$35.21 -0.18 (-0.51%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$35.36 +0.15 (+0.42%) As of 05/29/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Rezolute NASDAQ:RZLT$3.30 +0.03 (+0.92%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$3.29 -0.01 (-0.27%) As of 05/29/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.WAVE Life Sciences NASDAQ:WVE$6.58 +0.11 (+1.70%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$6.61 +0.03 (+0.44%) As of 05/29/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds These 3 Software Stocks Are Buying Back Shares Hand Over Fist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
